SPRB

Over the past six months, Spruce Biosciences' stock price has experienced significant volatility, with a remarkable increase of approximately 491.4% over the last year. Key events impacting the stock include a 21% drop in September 2026 following a $60 million public stock offering priced at $50 per share. The company announced positive pre-Biologics License Application (BLA) meetings with the FDA, confirming its plan to submit a BLA for TA-ERT for MPS IIIB in the fourth quarter of 2026, with the FDA supporting an accelerated approval pathway based on a surrogate biomarker, which is a significant catalyst. Spruce Biosciences expects to initiate the TrAnsform confirmatory study for TA-ERT in approximately 14 young children with severe MPS IIIB in Q4 2026. On August 12, 2026, the company reported a Q2 2026 EPS of -$6.68, missing the consensus estimate of -$5.79. Additionally, on August 4, 2025, the company executed a 1-for-75 reverse stock split.